GHRL and obesity due to melanocortin 4 receptor deficiency: Since the first description of GOAT in 2010, GOAT inhibitors have become a promising therapeutic strategy in the treatment of obesity and diabetes via their ability to increase insulin response and reduce ghrelin activity [153].